Biocon · NSE: BIOCON · BSE: 532523
Q3 FY26 results · Oct–Dec 2025
Biocon reported revenue from operations of ₹4,173.00 crore (up 9.2% from Q3 FY25) and net loss of ₹51.80 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,173.00 | 3,821.40 | +9.2% | 4,295.50 | −2.9% |
| Other income | 117.30 | 34.80 | +237.1% | 93.00 | +26.1% |
| Total income | 4,290.30 | 3,856.20 | +11.3% | 4,388.50 | −2.2% |
| Profit before tax | (67.80) | 155.90 | Turned loss | 171.30 | Turned loss |
| Net profit for the period | (51.80) | 81.10 | Turned loss | 132.80 | Turned loss |
| Attributable to shareholders of the company | 143.80 | 25.10 | +472.9% | 84.50 | +70.2% |
| EPS, basic (₹) | 1.08 | 0.21 | not comparable | 0.66 | +63.6% |
| Net margin (%) | -1.2 | 2.1 | 3.1 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 621.30 | 562.80 | +10.4% | 583.30 | +6.5% |
| Other income | 74.80 | 64.20 | +16.5% | 133.80 | −44.1% |
| Total income | 696.10 | 627.00 | +11.0% | 717.10 | −2.9% |
| Profit before tax | (84.50) | 603.90 | Turned loss | 85.70 | Turned loss |
| Net profit for the period | (76.40) | 584.00 | Turned loss | 70.90 | Turned loss |
| EPS, basic (₹) | (0.57) | 4.88 | not comparable | 0.55 | Turned loss |
| Net margin (%) | -12.3 | 103.8 | 12.2 |
Consolidated
- Filed with BSE
- 12 Feb 2026, 19:50 IST
- Board meeting
- 12 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Feb 2026, 19:50 IST
- Board meeting
- 12 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE